Science

Retatrutide: The Triple-Agonist GLP-1 Drug in Clinical Trials

GLP-1 Companion · 10 min read

Every few years, the obesity pharmacotherapy landscape shifts dramatically. Semaglutide changed expectations by achieving 15% weight loss in clinical trials — a threshold that, until 2021, had never been reached by a medication. Tirzepatide surpassed that with 20–22% weight loss by adding GIP receptor agonism to GLP-1. Now, a third molecule is in late-stage development that adds a third mechanism entirely — and the early data suggests it may approach the weight loss outcomes of bariatric surgery.

Retatrutide, developed by Eli Lilly, is a single injectable molecule that simultaneously activates three hormone receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This triple-agonist mechanism is what distinguishes it from every drug currently on the market. As of April 2026, retatrutide has not yet received FDA approval, but its NDA (New Drug Application) filing is expected in Q4 2026, with potential approval in 2027.

The Three Mechanisms: How a Triple Agonist Works

1. GLP-1 Receptor Agonism

GLP-1 (glucagon-like peptide-1) is the foundation of the mechanism. GLP-1 receptor activation reduces appetite by acting on hunger centers in the brain (particularly the hypothalamus and brainstem), slows gastric emptying so food stays in the stomach longer (producing satiety), and stimulates glucose-dependent insulin secretion from the pancreas. This is the same mechanism shared by semaglutide and tirzepatide.

2. GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) is the same second receptor activated by tirzepatide. GIP receptor agonism enhances insulin secretion, supports fat metabolism, and appears to amplify the appetite-suppressing effects of GLP-1 through still-investigated mechanisms. The addition of GIP is widely believed to be why tirzepatide produces significantly more weight loss than semaglutide despite both being once-weekly injections.

3. Glucagon Receptor Agonism

Glucagon receptor agonism is the unique addition in retatrutide, and it is the mechanism that has historically been considered most problematic in a diabetes medication. Glucagon raises blood sugar — it is the counter-regulatory hormone that opposes insulin. In traditional pharmacology, you would never intentionally activate the glucagon receptor in a drug intended for diabetes patients.

The key insight that makes retatrutide possible is that glucagon also has powerful metabolic effects unrelated to blood sugar: it increases resting energy expenditure (thermogenesis), promotes fat breakdown (lipolysis) in adipose tissue, and significantly reduces liver fat accumulation. At the doses and ratios used in retatrutide, the concurrent GLP-1 and GIP-driven insulin secretion effectively counterbalances the glucose-raising effect of glucagon, preventing meaningful hyperglycemia while preserving the fat-burning and metabolic rate benefits.

Phase 2 Results: The Study That Generated Global Interest

The Phase 2 trial of retatrutide was published in the New England Journal of Medicine in June 2023 and enrolled 338 adults with obesity. At the highest doses over 48 weeks, participants lost approximately 24% of their body weight. This was the highest Phase 2 result ever reported for any anti-obesity medication at the time of publication. The trial also demonstrated significant, dose-dependent reductions in liver fat content — findings with potential implications for metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH.

"The phase 2 data for retatrutide showed weight loss of up to 24% — a number that, five years ago, would have been considered impossible for a pharmacological intervention. It approaches what we see with gastric bypass surgery." — Obesity medicine specialist commentary on the NEJM 2023 publication

Phase 3 TRIUMPH-4 Results: Setting a New Record

The pivotal Phase 3 data for retatrutide in obesity without type 2 diabetes was published in December 2025 from the TRIUMPH-4 trial. The results confirmed and extended the Phase 2 signal:

• Mean body weight loss at 68 weeks: 28.7% from baseline — the highest ever recorded in a Phase 3 obesity trial
• Comparison context: tirzepatide achieved 22.5% (Zepbound), semaglutide achieved 15% (Wegovy), liraglutide achieved 8% (Saxenda)
• Significant reductions in waist circumference, blood pressure, triglycerides, and fasting glucose
• Substantial reductions in liver fat content across the cohort

An additional finding from TRIUMPH-4 was unexpected and has generated significant scientific interest: 75.8% reduction in knee osteoarthritis pain scores among participants with pre-existing knee OA. This effect appears to be driven by more than weight loss alone — the magnitude exceeded what would be predicted from weight reduction, suggesting potential direct anti-inflammatory effects of GLP-1 and/or glucagon receptor signaling in joint tissue. Further investigation is underway.

Ongoing Phase 3 Trials

The TRIUMPH program comprises multiple Phase 3 trials. TRIUMPH-4 (obesity without T2D) has reported results. TRIUMPH-1 (type 2 diabetes) is still awaiting full results publication. Additional TRIUMPH trials are examining cardiovascular outcomes, liver disease endpoints, and other populations. The breadth of the program reflects Eli Lilly's confidence in retatrutide as a potential multi-indication drug.

Safety and Side Effects in Phase 3

The side effect profile of retatrutide in Phase 3 was broadly consistent with what was observed in Phase 2 and is similar in character to other GLP-1 receptor agonists:

• Nausea: 30–40% (most common adverse event, highest during dose escalation)
• Diarrhea: 15–25%
• Vomiting: 10–18%
• Constipation: 10–15%
• GI effects were generally manageable with slow dose titration and resolved over time
• No unexpected or new safety signals were identified in Phase 3 beyond those known for the GLP-1 class

The addition of glucagon receptor agonism raised early concerns about potential effects on blood glucose, heart rate, and bone density. In Phase 3, modest increases in resting heart rate (similar in magnitude to injectable semaglutide) were observed. Blood glucose remained well-controlled. Bone density was monitored without evidence of accelerated bone loss attributable to the drug beyond what would be expected from substantial weight loss. Long-term safety data will continue to accumulate post-approval.

Regulatory Timeline and Approval Expectations

Eli Lilly has indicated that NDA filing for retatrutide is anticipated in Q4 2026, following completion and analysis of the full TRIUMPH trial program. The FDA standard review period is approximately 10–12 months, placing potential approval in late 2027. A priority review designation could accelerate this timeline. Given the magnitude of the efficacy data, designation as a Breakthrough Therapy — which the drug already held during development — may facilitate a more expedited review process.

Who Might Benefit Most From Retatrutide

If approved, retatrutide would not necessarily replace existing GLP-1 medications for all patients — but it may be most valuable for specific populations:

• Patients who have not achieved sufficient weight loss on tirzepatide (the current most effective approved option) — who represent a significant subset of the obesity treatment population
• Patients with Class III obesity (BMI ≥ 40) or super-obesity (BMI ≥ 50) who need maximum pharmacological efficacy
• Patients with metabolic dysfunction-associated steatohepatitis (MASH) who may benefit from the strong liver fat reduction signal
• Patients with obesity-related knee osteoarthritis, given the unexpected pain reduction finding
• Patients who prefer pharmacological therapy over bariatric surgery and need surgery-level weight loss

Putting Retatrutide in Context

It is worth stepping back to appreciate the pace of change in this field. A decade ago, a 5% weight loss from medication was considered a meaningful clinical outcome. Five years ago, 15% from semaglutide was considered transformative. The approval of tirzepatide at 22% pushed the bar higher. Retatrutide at 28.7% approaches the territory of bariatric surgery — a procedure that involves permanent anatomical changes and carries surgical risk. That a weekly injection could produce comparable outcomes is a genuine scientific milestone.

Equally important is the diversity of mechanisms now available. The evolution from single GLP-1 agonism, to dual GLP-1/GIP agonism, to triple GLP-1/GIP/glucagon agonism represents not just incremental improvement but a genuine expansion of understanding of how metabolic hormones interact. The insights from retatrutide's development will likely inform the next generation of obesity pharmacotherapy beyond this molecule.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.